Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Intravenous Cetirizine Prevents Infusion Reactions From Paclitaxel in Breast Cancer, Other Tumors

March 22nd 2021

Intravenous cetirizine showed comparable efficacy to IV diphenhydramine for the prevention of infusion reactions in patients with cancer who are undergoing treatment with an anti-CD20 antibody or paclitaxel.

Leading Cancer Researcher José Baselga Dies at 61

March 21st 2021

José Baselga, MD, PhD, a breast cancer pioneer and executive vice president of oncology R&D at AstraZeneca, passed away on Sunday at the age of 61.

Chemo Reigns Control in Early-Stage TNBC, But Immunotherapy, ADCs Gain Ground in Metastatic Setting

March 20th 2021

Anthracyclines and taxanes remain a backbone in the early-stage setting of triple-negative breast cancer as further evaluations of immunotherapy in the neoadjuvant and adjuvant settings needs to be conducted—efforts that will continue to shape the treatment paradigm.

Treatment Advances in HR+ Breast Cancer

March 19th 2021

A panel of experts who treat breast cancer close out a discussion on the use of newer therapies, including CDK4/6 inhibitors, based on outcomes demonstrated by recent clinical trials.

Case Discussion 2: Systemic Therapy for ER+, PR+, HER2- Breast Cancer

March 19th 2021

Breast oncologists review the appropriateness for treating a patient with ER-positive, PR-positive, HER2-negative breast cancer with systemic therapy, with special considerations regarding sequencing therapy if using a CDK4/6 inhibitor as adjuvant therapy.

The PRIME II Study in HR+ Breast Cancer

March 19th 2021

Andrew Seidman, MD, comments on results of the PRIME II study presented at SABCS and the appropriateness for radiation therapy in certain patient populations with HR-positive breast cancer.

Dr. George on Actionable Pathogenic Variants in Adults With Breast or Ovarian Cancers in the Caribbean

March 18th 2021

Sophia George, PhD, discusses actionable pathogenic variants in patients with breast cancer who live in the Caribbean.

Dr. Hurley on Breast Cancer Baseline Characteristics in the Caribbean Vs the United States

March 18th 2021

Judith E. Hurley, MD, discusses the baseline characteristics of patients with breast cancer in the Caribbean vs those in the United States.

Experts Take Stock of New CNS Data for HER2+ Metastatic Breast Cancer

March 18th 2021

Findings from recent analyses have kindled hope that novel agents with manageable toxicity profiles may begin to bridge the gap for patients with HER2-positive metastatic breast cancer.

Modernizing the Diagnosis of Male Breast Cancer

March 17th 2021

Although the majority of the patient population is made up of women, males represent 1 in 100 cases diagnosed in the United States each year.

Dr. Borgen on the Prognosis of Male Breast Cancer

March 16th 2021

Patrick Borgen, MD, discusses the prognosis of breast cancer in male patients.

Dr. Cortés on the Incidence and Management of Male Breast Cancer in Spain

March 16th 2021

Javier Cortés, MD, PhD, discusses the incidence and management of male patients with breast cancer in Spain.

Dr. Hurvitz on Incidence of Male Breast Cancer

March 13th 2021

Sara A. Hurvitz, MD, discusses the incidence of male breast cancer in the United States.

Sacituzumab Govitecan Sets the Stage for Substratification of TNBC

March 12th 2021

Aditya Bardia, MD, MPH, discusses the integration of ADCs and immunotherapy into the treatment landscape in metastatic TNBC and the future of AKT inhibitors in the field.

The PENELOPE-B Study in HR+ Breast Cancer

March 12th 2021

Dr Massimo Cristofanilli, of the Feinberg School of Medicine, describes the PENELOPE-B study of palbociclib and endocrine therapy for patients with HR-positive breast cancer at high risk of relapse after neoadjuvant chemotherapy.

Updated Results of MonarchE in HR+ Breast Cancer

March 12th 2021

Dr Sara Tolaney comments on recent updates of the monarchE trial of abemaciclib and adjuvant endocrine therapy for high-risk early stage breast cancer as presented at SABCS 2020.

FDA Will Reassess 6 Immunotherapy Accelerated Approvals

March 12th 2021

Six indications for immune checkpoint inhibitors granted under the FDA’s accelerated approval process that later failed confirmatory clinical trials are being reassessed as the agency continues an industry-wide evaluation of the pathway.

Kalinsky Sees Growing Excitement Over ADCs in HER2-Negative Breast Cancer

March 11th 2021

The FDA's accelerated approval of sacituzumab govitecan-hziy in April 2020, filled a previously undefined role for antibody-drug conjugates in patients with triple-negative breast cancer.

Checkpoint and PARP Inhibition Remain the Focus of Ongoing Research in TNBC

March 10th 2021

The field of triple-negative breast cancer is pushing to improve treatment by answering questions regarding biomarkers of response, defining the utility of neoadjuvant approaches, and exploring potential combinations with checkpoint inhibitors and PARP inhibitors.

Modern Approaches to Brain Cancer Metastases in Breast Cancer

March 10th 2021

Prognosis and treatment recommendations for patients with breast cancer and brain metastases rely heavily on the tumor subtype; however, evolving evidence demonstrates that receptor expression and subtype grouping may change during the course of the patient’s disease.